Research presented at the 22nd Annual International Meeting of The International Society for Pharmacoeconomics and Outcomes Research demonstrates gaps in physicians’ education on biosimilar agents.
Research presented at the 22nd Annual International Meeting of The International Society for Pharmacoeconomics and Outcomes Research demonstrates gaps in physicians’ education on biosimilar agents.
Researchers from Cardinal Health Specialty Solutions sought to assess community oncologists’ understanding of biosimilars by surveying a group of 61 community-based US oncologists and hematologists during a live meeting. The clinicians—who came from practices of all sizes and from across the United States—were asked to respond to specific multiple-choice questions about their perceptions of biosimilar agents.
The results of the survey showed that, when asked to describe their familiarity with biosimilars, many physicians reported a lack of clarity about the products:
The survey also revealed that, with respect to safety and efficacy considerations, many clinicians appear receptive to biosimilars, though some seek more information before they will consider prescribing them:
Cost savings appear to be an important factor in clinicians’ willingness to prescribe biosimilar agents rather than reference products:
The survey also asked clinicians to consider patient case examples for 5 conditions, and to report how likely they were to prescribe a biosimilar over a reference product to treat each condition. The reported likelihood of the respondents to prescribe biosimilars is as follows:
The researchers concluded that, while clinicians appear receptive to the idea of prescribing biosimilar products in oncology, significant gaps in education pose a barrier to physicians’ acceptance of these products. It will be critical, the researchers suggest, to overcome this educational barrier in order to increase the uptake of biosimilars and to realize cost-savings in patient treatment.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Addressing Patent Abuse, Reimbursement Models Key to Sustainable Biosimilar Market
April 25th 2025Sonia T. Oskouei, PharmD, emphasized strategies to streamline regulations and evolve to overcome barriers and expand the availability of cost-effective biosimilar treatments across more therapeutic areas.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Decade of Biosimilars Yields $36 Billion in Savings and Strengthens Supply Chain
April 24th 2025Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply chain, but continued education and a robust pipeline are crucial for future growth.